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Abstract
Objective—To describe a number of conditions and therapies associated with multiple organ 
dysfunction syndrome (MODS) presented as part of the Eunice Kennedy Shriver National Institute 
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of Child Health and Human Development MODS Workshop (March 26–27, 2015). In addition, the 
relationship between burn injuries and MODS is also included although it was not discussed at the 
Workshop.
Data Sources—Literature review, research data, and expert opinion.
Study Selection—Not applicable.
Data Extraction—Moderated by an expert from the field, issues relevant to the association of 
MODS with a variety of conditions and therapies were presented, discussed and debated with a 
focus on identifying knowledge gaps and research priorities.
Data Synthesis—Summary of presentations and discussion supported and supplemented by 
relevant literature.
Conclusions—Sepsis and trauma are the two conditions most commonly associated with 
MODS both in children and adults. However, many other pathophysiologic processes may result in 
MODS. In this paper, we discuss conditions such as liver failure and pancreatitis, pathophysiologic 
processes such as ischemia and hypoxia, and injuries such as trauma and burns. Additionally, 
therapeutic interventions such as medications, blood transfusions, transplantation may also 
precipitate and contribute to MODS. The purpose of this manuscript is to describe the association 
of MODS with a variety of conditions and therapies in an attempt to identify similarities, 
differences and opportunities for therapeutic intervention.
Keywords
Multiple organ dysfunction syndrome; pancreatitis; liver failure; solid organ transplant; cirrhosis; 
burns; trauma; transfusion; pediatrics
Introduction
There are a number of pathophysiologic processes that may result in the multiple organ 
dysfunction syndrome (MODS) in children. To begin, underlying diagnoses such as cancer 
and congenital heart disease as described in Part 1 of this manuscript, as well as inborn 
errors of metabolism, rheumatologic diseases and various others have been associated with a 
predisposition to the syndrome. Similarly, acute conditions such as sepsis, acute respiratory 
distress syndrome, acute kidney injury, liver failure, and pancreatitis have also been 
associated with the process. Additionally, pathophysiologic processes such as hypoxia (of 
any source) can be potent triggers of MODS as observed following cardiopulmonary arrest. 
Further, acute insults such as multiple trauma and thermal injuries have also been found to 
result in MODS. Conversely, numerous treatments and therapeutic regimens such as anti-
neoplastic therapies, blood transfusions, hematopoietic and solid organ transplantation have 
all been reported to elicit MODS. Given the breadth of these various topics, any attempt to 
provide a comprehensive review of the many etiologies of MODS would be grossly 
insufficient, and thus, that is not the intent of this manuscript. Conditions commonly 
associated with MODS such as inborn errors of metabolism, brain injury and neurologic 
insults and rheumatologic disorders are not addressed in this, or its accompanying 
manuscript. The available literature contains a host of publications and reviews addressing 
these individual topics and their association with MODS. The purpose of this manuscript, in 
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conjunction with Part 1, is simply to encourage investigators to consider the topic from the 
perspective of other disciplines to hopefully identify areas of commonality, enhance the 
body of knowledge of other disciplines, and identify opportunities for future study.
Hepatic failure/Solid organ transplantation
MODS is a critical problem for patients who receive solid organ transplantation, as well as 
those with disease processes that put them at risk for requiring a transplant such as acute and 
chronic liver failure. As with other causes of MODS, disordered regulation of the immune 
system and endothelial dysfunction play a central role in these processes. Consequently, an 
understanding of the clinical phenotypes and/or mechanisms of injury associated with 
MODS in patients with acute and/or chronic liver failure or in solid organ transplant 
recipients may help inform MODS in other disease processes.
Cirrhosis
In cirrhosis, vasodilatation occurs in the systemic vasculature and in the splanchnic vascular 
bed in response to liver fibrosis as portal hypertension results in poor clearance of vasoactive 
peptides which promotes endothelial dysfunction. This endothelial dysfunction, in turn, 
decreases afterload and promotes excessive myocardial contractility. As a result, systolic 
function is not only disproportionately high, but diastolic function, or relaxation becomes 
compromised (1,2). Such alterations in cardiac function may be clinically silent, until made 
evident by intercurrent stress. Moreover, dilatation of the pulmonary vasculature in cirrhosis 
may result in hepatopulmonary syndrome secondary to right to left shunting of blood 
through pulmonary angiomas. Further, the renin-angiotensin-aldosterone system is activated 
in response to the dilatation of the systemic vascular bed resulting in the release of 
vasopressin and an increased risk for hepatorenal syndromes Type I and II. Each of the 
pulmonary and renal changes is associated with pre-transplant morbidity and justifies Model 
for End-Stage Liver Disease (MELD) and Pediatric End-Stage Liver Disease (PELD) 
exception points. In the end, all changes directly or indirectly reflect altered endothelial 
function.
Acute on Chronic Liver Failure
Acute decompensation of cirrhosis versus acute on chronic liver failure (ACLF) is 
distinguished by the presence of organ failure (1,3,4). In the former, increased fibrosis and 
portal hypertension is associated with vasodilatation and complications of portal 
hypertension. With acute on chronic liver failure, bacterial translocation across the intestine 
occurs in the setting of decreased immune surveillance of the innate and adaptive immune 
systems. This bacterial infection is associated with worsening systemic hemodynamics and 
MODS. Transplant free mortality is increased 5-fold in adults with ACLF (51%, 90-day 
mortality) compared to acute decompensation of cirrhosis (10%, 90-day mortality). The 
number of organ failures is directly related to the risk of mortality and disease severity tools 
for liver disease (i.e. MELD, PELD) do not accurately reflect risk.
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Acute Liver Failure
Acute liver failure is a devastating condition which may commonly be associated with 
MODS including renal, bone marrow and central nervous system failure (4). The primary 
etiology is not established in almost 50% of children (5). Liver transplantation can serve as 
directed therapy for patients with acute liver failure when treatment fails to rescue the patient 
from clinical deterioration. While liver transplantation may be life-saving, the decision to 
proceed with transplantation is irreversible and has profound consequences, both on organ 
allocation and on long term challenges faced by the patient and family. Patients who receive 
transplantation for pediatric acute liver failure have increased short-term and long-term 
mortality risk compared to those with chronic liver disease. Death in the immediate post-
transplant period is usually attributed to MODS, sepsis, or cerebral edema. Patients with 
indeterminate acute liver failure have excess late mortality risk most commonly related to 
sepsis; they are also at increased risk for developing aplastic anemia.
As part of the pediatric acute liver failure effort (U01 DK072146 Squires), markers of 
immune activation were measured in 77 children with acute liver failure (6). The normalized 
serum sIL2Rα level was higher in patients who died (p=0.02) or underwent liver transplant 
(p=0.01) compared to those who survived with native liver (7). Of the 15 subjects with 
markedly high sIL2Rα levels (≥5000 IU/mL), 5 survived with their native liver, 2 died, and 
8 underwent liver transplant (7). The investigators subsequently analyzed serum 
inflammatory mediators and found that liver transplant recipients had a biomarker pattern 
more similar to spontaneous survivors than those of non-survivors (8). If confirmed, such 
findings might allow for the use of immunomodulatory therapy to improve outcomes and 
potentially decrease the use of liver transplants (Table).
Solid Organ Transplantation
Thrombotic microangiopathy (TMA), recognized as a cause of morbidity and mortality in 
stem cell transplant recipients (see Part 1), is increasingly detected in solid organ transplant 
recipients (9,10). TMA results from dysregulation of complement activation. With solid 
organ transplant recipients, endothelial injury and microangiopathy are likely multifactorial 
reflecting ischemia reperfusion injury associated with transplant, infections, inherited or 
acquired complement dysregulation and injury from exposure to medications such as 
calcineurin inhibitors. As a result of uncontrolled complement activation, patients with TMA 
have hemolytic anemia, pulmonary hypertension and renal insufficiency with evidence of 
gastrointestinal and central nervous system injury. The risk of death is related to the number 
of involved organs. Early data suggest that blockage of terminal steps in complement 
activation with ecluzimab may mitigate injury (11).
Summary
MODS is a critical problem with acute and chronic liver failure and for those who receive 
solid organ transplant. It appears that immune dysregulation and endothelial dysfunction 
play a central role in the pathogenesis of MODS. Current disease stratification tools are 
inadequate, and therefore, we cannot effectively predict which patients are at risk or how 
risk evolves over time. Understanding the pathobiology, and the development of risk 
stratification tools using molecular and computational techniques would guide risk 
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stratification, permit trials targeted to mitigate injury, improve organ allocation and decrease 
mortality.
Pancreatitis
In addition to liver disease, other disease processes of the gastrointestinal tract may be 
associated with MODS. For example, there has been a rising trend in the number of patients 
presenting with acute pancreatitis in the past decade (12). With this increase, there has also 
been an increase in the number of patients who are developing MODS in the setting of acute 
pancreatitis. However, the reasons that drive a sub-population of patients with pancreatitis to 
develop MODS and the process by which acute pancreatitis transitions to MODS are not 
well understood (Table). Some experts are unsure whether pancreatitis is a primary driver or 
a byproduct of MODS.
In recent years, the pathophysiology of pancreatitis has been the focus of multiple 
laboratories throughout the world. Still, the molecular details of the events that lead to 
pancreatitis remain uncertain. A number of hypotheses have been offered (12–14). Many 
center on the premature activation of trypsinogen within the acinar cell. Other models invoke 
excessive activation of the unfolded protein response, which results in activation of cell-
death pathways. In each case, the damage to acinar cells triggers an inflammatory response 
and the release of digestive enzymes into the circulation.
Some experts speculate that the increased levels of pancreatic digestive enzymes in the 
bloodstream may lead to an imbalance in cytokines resulting in MODS (12,15). Others 
propose that MODS develops as a result of a robust local inflammatory response (15). Still 
others suggest that MODS occurs primarily in the setting of infected pancreatic necrosis and 
sepsis (16). Regardless of the trigger, patients with MODS present with a systemic 
inflammatory response syndrome (SIRS) and/or a compensatory anti-inflammatory response 
syndrome (CARS) (14,17). In the case of SIRS, there is an activation of the vascular 
endothelium, neutrophils, and biological defenses, which results in early-phase 
complications and morbidity, eventually resulting in the occurrence of MODS (13). In 
CARS, there is an excessive anti-inflammatory response and compromised immune 
function, which leads to late-phase complications such as infected pancreatic necrosis and 
abscess formation. The data supporting these models are sparse. It is important to gain a 
better understanding of the pathophysiological changes at the level of the pancreas that incite 
the downstream effects that culminate in MODS.
In addition, there would appear to be an immediate need for the validation in children of 
criteria used in adults to diagnose acute pancreatitis including prospective studies that 
standardize etiological classifications (12,17). Additionally, multicenter studies on the 
natural history of this disease in children would also appear needed in order to understand 
factors predicting disease severity and complications (12). Finally, it would seem important 
for a better understanding of the molecular details of acute pancreatitis to be attained 
(Table). The development of better research models, particularly to elucidate the 
mechanisms of genetic risk factors, would seem essential to facilitating such an 
understanding.
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Acute Kidney Injury
Acute kidney injury (AKI) occurs between 20–60% of children and neonates admitted to 
critical care units (18). This wide range likely reflects, to some degree, the variability in 
definitions used to identify and diagnose AKI. Over the past decade, the use of the RIFLE, 
pRIFLE, AKIN and KDIGO guidelines have been created to give a more definitive ranking 
of the degree of AKI based on a rising serum creatinine level and/or diminishing urine 
output (19). Additionally, biomarkers (e.g. NGAL, KIM1, IL-18) are being used as research 
tools to identify “subclinical” AKI (20). Prior to these various tools, the literature based 
definition of AKI was often simply the need for renal replacement therapy (RRT) (21). Data 
suggest that the need for RRT is associated with a greater risk of death (22). In fact, the 
presence of AKI is associated with increased mortality in children; recent data reveal that 
early AKI is associated with a seven-fold increase in mortality (23). Among children with 
acute decompensated heart failure, the presence of worsening renal function (defined as a 
serum creatinine increase ≥ 0.3 mg/dL) was associated with a ten-fold increase in the 
combined endpoint of either death or the need for mechanical circulatory support (24). 
Among children with sepsis and MODS, the development of AKI is a discouraging 
prognostic sign (25)
As with other organ injuries, AKI may be the precipitant of MODS or one of the organs 
injured as part of the syndrome. Not surprisingly, the presence of MODS has been 
associated with increased mortality among children who receive continuous RRT (CRRT) 
for any indication (26). The use of CRRT associated with MODS is frequently in the setting 
of sepsis. In the Surviving Sepsis Management Guidelines, CRRT is suggested to facilitate 
fluid management in hemodynamically unstable septic patients, and specifically for children, 
to prevent ≥ 10% fluid overload (27). The indication for CRRT commencement in this 
setting is often for hypermetabolic syndrome associated with fluid overload. In this clinical 
condition, CRRT may facilitate effective fluid management removing sufficient fluid to 
prevent symptomatic overload and allowing for the provision of adequate nutrition and 
necessary medications. Temperature control is also effectively achieved and maintained with 
the use of CRRT. Although the true benefit of CRRT in this setting remains to be clearly 
established, some data suggest benefit with its use among children with multiple organ 
failure (28). A miniaturized Cardio-Renal Pediatric Dialysis Emergency Machine 
(CARPEDIEM®) has been developed and published case reports suggest its benefit in 
neonates with MODS (29,30).
Burn patients
In addition to medical conditions, MODS has also been associated with a host of external 
injuries including multiple trauma patients and burn victims. Although not discussed as a 
separate topic at the Workshop, this section is included given the prevalence of burn injuries 
in children and their association with MODS. For example, a recent, relatively large single 
center trial reported MODS to occur in 19% of children with a burn area that encompassed 
at least 30% of the body surface area (31). Moreover, pediatric burn patients represent a 
unique group with a profound and poorly understood dysfunctional immune, metabolic, and 
catabolic response commensurate to the original size of the thermal injury (32). 
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Physiologically, the post burn response is manifested by metabolic rates well above normal, 
increased cardiac work, muscle protein catabolism, profound lipolysis, insulin resistance and 
liver dysfunction (33). Virtually every organ system is affected by major burn injury with 
perturbations mediated by surges in catecholamines, cortisol, glucagon and pro- and anti-
inflammatory cytokines (33). In one study, MODS was found to be associated with the size 
of the burn, full thickness burns, and an associated inhalational injury. Not surprisingly, the 
occurrence of MODS was associated with a longer length of ICU stay, a greater number of 
major infections, and a substantially higher mortality.
Research over the last fifty years has focused on defining the clinical challenges encountered 
from the onset of thermal injury: the resuscitation, the acute hospitalization, and the 
rehabilitation. Encouragingly, substantial gains in the understanding of the clinical response 
have resulted in improvements in morbidity and mortality. Current standards of care 
underscore these advances and awareness: early excision and grafting, early enteral 
nutrition, and environmental thermoregulation (33). As knowledge is gained and care 
informed, new and deeper questions arise that must be addressed. For example, the 
hyperdynamic metabolic and catabolic response associated with major pediatric burn clearly 
contributes to the risk of MODS (Table). To address these concerns and attenuate the 
pervasive growth retardation after severe burns, early enteral nutrition, based on metabolic 
carts has become standard (33). Other strategies, such as increased ambient temperatures in 
the operating and hospital room successfully limit metabolic rates and substantially improve 
gains associated with early enteral nutrition (33). However, as composition of standard tube 
feedings change, maintaining the balance between increasing lean body mass versus fat gain 
has been a challenge. It is not definitively established whether supplementation with 
arginine, high dose glutamine, or other amino acids will benefit this patient population (34).
Additionally, propranolol administration during acute hospitalization has been found to 
mitigate the marked tachycardia and increased cardiac work observed in severely burned 
children (35–43). Benefits associated with propranolol use include decreased metabolic 
rates, lean body mass gains, and more efficient myocardial oxygen consumption. However, 
the definitive role of propranolol in this population is still not fully known, and multi-center 
study is ongoing to best delineate its value. Further, oxandrolone has been found to decrease 
whole body catabolism, and counter the decreased strength and growth retardation observed 
in large burns. However, the long term effects of this agent need to be demonstrated, both 
alone and in combination with other anti-catabolic agents such as propranolol (43–48). 
Insulin resistance has been noted in severely burned pediatric patients starting during the 
acute hospitalization and lasting for three years. Better blood glucose control has led to 
better outcomes in some populations, but optimal management of hyperglycemia and insulin 
resistance in these children remains unknown (49–52).
Given the magnitude of the physiological response to major burn injury, there is a need to 
understand the role of genetics in the response, whether it be in the response to resuscitation 
or in the development of hypertrophic scars. Several groups are focusing on the genomic and 
proteomic response to burn injury in children and identifying the genotypes and phenotypes 
of survivors and non-survivors in order to evaluate treatment algorithms and/or predict 
outcomes (53–55). Specifically, groups are looking at genomic and proteomic profiles to try 
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to determine who is a risk for developing MODS in order to improve morbidity and 
mortality (31). In one small, multicenter study of burn victims, proteomic analysis revealed 
differences in the level of acute phase reactants, proteins of inflammation, complement, 
hepatic signaling proteins, and proteins associated with insulin resistance that distinguished 
survivors from non-survivors. In particular, among the cytokines assessed, non-survivors 
were characterized by higher serum levels of GM-CSF, IL-8, IL-4 and MCP-1 (p < 0.05) 
(53).
Trauma
Pediatric major trauma patients are also at risk for MODS; data suggest that MODS occurs 
in as many as 12% of children admitted to a pediatric intensive care unit with an injury 
severity score greater than nine (56). Much of that morbidity would appear to be associated 
with traumatic brain injury as the incidence of MODS in pediatric trauma patients decreases 
substantially when TBI patients are excluded from analysis (57). The pathogenesis of 
MODS associated with pediatric trauma is just beginning to be elucidated, but would appear 
to emanate from a variety of potential causes including inflammation, immune dysfunction, 
endothelial injury, secondary infection and hemorrhage. Data suggest that IL-6 levels are 
elevated in critically injured children with some data suggesting an association between 
these levels and the occurrence of MODS (56, 58). Additionally, immune paralysis has also 
been reported in critically injured pediatric trauma patients using ex vivo 
lipopolysaccharide-induced tumor necrosis factor alpha production capacity assessments 
(58). Moreover, nosocomial infections appear to be more common in the trauma patients 
who have this documented impediment in their immune response.
In addition to the inflammatory changes and perturbations, hemorrhage, the associated 
coagulopathy and the use of transfusion may also contribute to the promulgation of MODS 
among the pediatric trauma population (Table). For example, among the 8–10% of pediatric 
trauma patients who require transfusion under current Advanced Trauma Life Support 
(ATLS) guidelines, mortality is reported to approximate 30% (59).
Recent data suggest that 30–77% of pediatric trauma patients have some degree of 
coagulopathy upon admission, with a higher incidence and severity in patients with a 
concomitant traumatic brain injury (59–61). Many adult trauma centers have recognized this 
“trauma associated coagulopathy” (TAC), and early balanced ratio transfusion/resuscitation 
protocols have been implemented. Typically, these protocols use 1:1:1 ratios of packed red 
blood cells (RBCs), fresh frozen plasma (FFP), and platelets, or some variation initially—
followed by thromboelastography (TEG)-driven component transfusions. Such an approach 
has not gained widespread acceptance among the pediatric community. The natural history 
of TAC in children needs to be better delineated and understood in the context of injury 
severity. The role of TEG-driven resuscitation protocols in decreasing the morbidity and 
mortality associated with pediatric trauma including the occurrence of MODS should be 
established. Given the body of evidence suggesting an association between transfusion and 
organ dysfunction, a better understanding of the optimal approach to transfusion therapy in 
pediatric trauma patients may result in improved outcomes.
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Red blood cell transfusion therapy
The association of RBC transfusion as well as native RBC dysfunction with organ failure 
progression in the setting of MODS has been broadly reported and is an active field of 
investigation (62). The principle RBC function is to enable oxygen (O2) delivery, the 
maintenance of which is fundamental to supporting those with critical illness and is an 
integrated function of blood O2 content and flow. It is essential to note that blood flow 
(rather than O2 content) is the focus of physiologic control in O2 delivery homeostasis (63). 
O2 content varies within a fairly narrow range, whereas flow is scalable by several orders of 
magnitude. Thus, the volume and distribution of blood flow vary to maintain coupling 
between O2 delivery and demand (64–66). In addition to conventionally appreciated features 
of RBC physiology influencing O2 delivery (O2 affinity and rheology), mounting evidence 
supports an expanded paradigm for O2 delivery homeostasis based on coordinated gas 
transport (O2, carbon dioxide (CO2), and nitric oxide (NO)) which is linked to vascular 
signaling by RBCs (67,68). Thus, it has come to be understood that the trapping, processing 
and delivery of NO by RBCs has emerged as a conserved mechanism through which 
regional blood flow is linked to biochemical cues of perfusion sufficiency (69,70). By 
coordinating vascular signaling in a fashion that links O2 and NO flux, RBCs couple small 
vessel caliber (and thus blood flow) to O2 need in the tissues (71–74). Malfunction of this 
signaling system is implicated in a wide array of pathophysiologic processes and may be 
explanatory for the dysoxia frequently encountered in the critical care setting (62).
Moreover, it is now recognized that donor RBCs are fundamentally altered during 
processing and storage in a manner that both impairs O2 transport efficacy and introduces 
additional risk by perturbing both immune and coagulation systems in transfusion recipients 
(75–80). The protean biophysical and physiological changes in RBC function arising from 
storage are termed the “storage lesion”; many have been understood for some time. For 
example, it is known that the O2 affinity of stored blood rises during the storage period and 
that intracellular allosteric regulators, notably 2,3-disphosphoglyceric acid and adenosine 
triphosphate (ATP), are depleted during storage (78,81). The appreciation of other storage 
lesion features has emerged with improved understanding of coagulation, immune, and 
vascular signaling systems (75). Recent data further implicate RBC processing and storage 
in disturbance of key RBC signaling regulating the linkage between regional blood flow and 
regional O2 consumption (by regulating the bioavailability of key vasoactive mediators in 
plasma as described above). In summary, RBC transfusion always results in an increased 
arterial O2 content, but the signaling disturbance and the compensatory mechanisms to 
anemia described above may explain the surprising lack of efficacy for transfusion in 
improving O2 delivery in critically ill patients with anemia (82–89). The failure of RBC 
energetics and antioxidant systems is emerging as a likely mechanism for both the ‘storage 
lesion’ and the acquired dysfunction of endogenous RBCs in the setting of MODS (90,91).
Although RBC transfusion increases hemoglobin concentration, and thereby blood O2 
content, it does not necessarily follow that O2 delivery is likewise increased unless blood O2 
content is rate-limiting in the transfer of O2 from lung to tissue. The current approaches to 
transfusion decision-making in the critical care setting are to maintain an ‘adequate’ RBC 
mass well above a threshold that may limit tissue O2 delivery. Historically, ‘normal’ values 
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have been presumed necessary for ‘adequate reserve’ during stress, although awareness of 
the tolerance for anemia in this population is developing (92–94). With an improved 
understanding of vascular signaling and gas transport by RBCs (67,69,95), and of the full 
array of defects comprising the RBC ‘storage lesion’ (75,83), it is now appreciated that this 
strategy must be balanced by consideration that: (1) donor and recipient RBCs do not exhibit 
similar physiology and (2) RBC transfusion may cause harm (beyond transfusion reactions 
and transmission of infection) – and that this harm appears progressive with transfusion 
volume, frequency and donor exposure. Consequently, newer ‘restrictive’ hemoglobin 
thresholds for transfusion (approximately 7 gm/dL) are now appreciated to be at least non-
inferior (and in many cases, superior) to more ‘liberal’ hemoglobin thresholds 
(approximately 9 gm/dL) for a broad array of conditions (96–102), even in actively bleeding 
patients (103). While traditional transfusion thresholds are currently undergoing a broad 
‘reset’, a comprehensive paradigm shift is emerging in the approach to the critically ill, with 
re-consideration of the ‘hemoglobin trigger’ strategy. Clearly, it is not feasible to define 
specific hemoglobin boundaries across the complex interaction of developmental-, 
condition- and stress-specific situations in the intensive care unit. Ideally, the decision to 
transfuse should be based upon individual and context-specific considerations of the degree 
to which anemia contributes to tissue O2 delivery lack (and/or reserve) (104–107). This 
distinction is exemplified by employing ‘physiologic’ triggers (e.g. transfusing only to 
rectify abnormal measures of perfusion sufficiency (or reserve)), rather than to maintain a 
specific hemoglobin concentration, irrespective of context (108,109). In order to do so, it is 
necessary to identify the specific physiologic goal(s) most linked to outcome as well as to 
determine appropriate thresholds for putative goals. An enhanced ability to assess the 
functionality of the circulating RBC mass and its specific relationship to tissue oxygen 
delivery is pivotal to such determinations.
Transfusion decisions, particularly among the critically ill, should maintain hemoglobin 
levels above thresholds that limit O2 delivery. Historically, normal values were presumed 
necessary during stress. There is now a better appreciation of anemia tolerance and donor 
RBC impairment; consequently, conservative transfusion approaches are emerging, based 
upon non-inferiority trials of permissive anemia (e.g. restrictive hemoglobin-based 
thresholds). However, there is a lack of decision-making structure that identifies specific 
individuals for whom permissive anemia is unsafe and guides transfusion both in terms of 
timing and amount based upon outcome-linked physiologic O2 delivery targets. Prior to 
implementation of this approach, the ability to quantify O2 delivery/consumption and 
sufficiency/reserve relationships (global/organ/tissue) and the ability to specifically attribute 
these parameters to anemia must be developed (Table).
Conclusion
In summary, there are a number of medical conditions, external injuries and therapeutic 
interventions that are associated with multiorgan dysfunction and the MODS. The intent of 
this manuscript was to highlight a handful of those conditions, injuries and therapies in an 
attempt to identify areas of commonality, areas of difference, and opportunities for further 
study and intervention; it was not to present an exhaustive list of the many etiologies that 
may result in MODS. It is hoped that by considering this syndrome in relation to a number 
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of disparate conditions, investigators may gain new insight and avenues for study that will 
advance the understanding of this process from that of a syndrome, a collection of 
symptoms, to a well defined clinical entity with established pathophysiologic causes, genetic 
predispositions and targeted therapies.
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Table
Identified Knowledge Gaps and Potential Opportunities for Study
• Current disease stratification tools of acute and chronic liver failure are inadequate, and therefore, it is difficult to effectively 
predict which patients are at risk or how risk evolves over time. Understanding the pathobiology, and the development of risk 
stratification using molecular and computational techniques would potentially guide risk stratification, permit trials targeted to 
mitigate injury, improve organ allocation and decrease mortality.
• A better understanding of serum inflammatory mediators and biomarker patterns in acute liver failure might help distinguish 
spontaneous survivors from non-survivors and allow for the use of immunomodulatory therapy to improve outcomes and 
potentially decrease the use of liver transplants.
• There appears to be a need for the validation in children of criteria used in adults to diagnose acute pancreatitis including 
prospective studies that standardize etiological classifications.
• The natural history of pancreatitis in children needs to be better established in order to understand factors predicting disease 
severity, complications and the progression to MODS.
• A better understanding of the molecular details associated with acute pancreatitis and their relationship to MODS needs to be 
attained.
• The mechanisms by which acute kidney injury precipitate dysfunction in other organs are not clearly established; conversely, the 
mechanisms by which the kidney is secondarily injured as part of MODS are also not well understood.
• An expansion of the understanding of the manner by which the hyperdynamic metabolic and catabolic responses associated with 
major pediatric burn contribute to the risk of MODS may result in better outcomes.
• Further work assessing the genomic and proteomic profiles associated with burn injury may help to improve morbidity and 
mortality and reduce the incidence of MODS in this patient population.
• A better understanding of the inflammatory and counter-inflammatory changes associated with major trauma is needed; such 
insight might afford opportunities to intervene and mitigate the occurrence and severity of associated MODS.
• The natural history of trauma associated coagulopathy in children needs to be better delineated and understood in the context of 
injury severity. The role of thromboelastography driven resuscitation protocols in decreasing the morbidity and mortality 
associated with pediatric trauma warrants investigation.
• A decision-making structure is needed to guide red blood cell transfusion both in terms of timing and amount based upon 
outcome-linked physiologic O2 delivery targets.
• The ability to quantify O2 delivery and consumption measurements, to relate these measurements to O2 sufficiency and reserve at 
the whole body, organ, and tissue levels, and to attribute these parameters to anemia must be developed.
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